Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53

Oxaliplatin resistance is a major issue in the treatment of p53 mutant colorectal cancer (CRC). Finding the specific biomarkers would improve therapeutic efficacy of patients with CRC. In order to figure out the biomarker for CRC patients with mutant p53 access oxaliplatin, a Gene Expression Omnibus...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei-Lin, Batzorig, Uyanga, Hung, Chin-Sheng, Wei, Po-Li, Huang, Chien-Yu, Chang, Yu-Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844434/
https://www.ncbi.nlm.nih.gov/pubmed/35178443
http://dx.doi.org/10.1155/2022/1322788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844434/
https://www.ncbi.nlm.nih.gov/pubmed/35178443
http://dx.doi.org/10.1155/2022/1322788

Ejemplares similares